MX2022015500A - Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico. - Google Patents

Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Info

Publication number
MX2022015500A
MX2022015500A MX2022015500A MX2022015500A MX2022015500A MX 2022015500 A MX2022015500 A MX 2022015500A MX 2022015500 A MX2022015500 A MX 2022015500A MX 2022015500 A MX2022015500 A MX 2022015500A MX 2022015500 A MX2022015500 A MX 2022015500A
Authority
MX
Mexico
Prior art keywords
liver disease
fatty liver
nonalcoholic fatty
prophylactic
therapeutic drug
Prior art date
Application number
MX2022015500A
Other languages
English (en)
Inventor
Yusuke Sasaki
Toshiya Tanaka
Masato Asahiyama
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2022015500A publication Critical patent/MX2022015500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención aborda el problema de proporcionar una composición medicinal y una combinación de fármacos mediante la cual puede prevenirse y/o tratarse enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica. La presente invención proporciona una combinación de un agonista de receptor activado por proliferador de peroxisoma a con un inhibidor de cotransportador 2 de glucosa de sodio (SGLT2), la cual va a ser usada para prevenir y/o tratar enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica.
MX2022015500A 2017-01-11 2019-07-10 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico. MX2022015500A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017002731 2017-01-11

Publications (1)

Publication Number Publication Date
MX2022015500A true MX2022015500A (es) 2023-01-24

Family

ID=62840012

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008317A MX2019008317A (es) 2017-01-11 2018-01-11 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
MX2022015500A MX2022015500A (es) 2017-01-11 2019-07-10 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008317A MX2019008317A (es) 2017-01-11 2018-01-11 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Country Status (11)

Country Link
US (2) US20200022960A1 (es)
EP (1) EP3569250A4 (es)
JP (2) JP7202892B2 (es)
KR (1) KR102487075B1 (es)
CN (1) CN110167595A (es)
AU (1) AU2018206907B2 (es)
BR (1) BR112019013539A2 (es)
CA (1) CA3047716A1 (es)
MX (2) MX2019008317A (es)
RU (1) RU2019123735A (es)
WO (1) WO2018131626A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
EP3906022A1 (en) * 2018-12-31 2021-11-10 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220193102A1 (en) * 2019-04-02 2022-06-23 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
CN117677385A (zh) 2021-05-27 2024-03-08 兴和株式会社 用于治疗肝病的培马贝特和/或托格列净

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080990A1 (ja) 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
KR100515360B1 (ko) 2003-09-02 2005-09-15 삼성에스디아이 주식회사 플라즈마 표시 패널 및 그의 구동 방법
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
EP1782828B1 (en) * 2004-07-21 2016-06-29 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
KR20150005365A (ko) 2013-07-05 2015-01-14 에스케이하이닉스 주식회사 주기신호생성회로
TWI696462B (zh) 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
RU2695652C2 (ru) * 2014-09-25 2019-07-25 Астразенека Аб Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени

Also Published As

Publication number Publication date
US20200022960A1 (en) 2020-01-23
JPWO2018131626A1 (ja) 2019-11-07
JP7202892B2 (ja) 2023-01-12
US20220054459A1 (en) 2022-02-24
EP3569250A4 (en) 2020-11-04
RU2019123735A (ru) 2021-02-12
KR20190104542A (ko) 2019-09-10
EP3569250A1 (en) 2019-11-20
KR102487075B1 (ko) 2023-01-09
JP2023024728A (ja) 2023-02-16
BR112019013539A2 (pt) 2020-01-07
CN110167595A (zh) 2019-08-23
MX2019008317A (es) 2019-09-19
WO2018131626A1 (ja) 2018-07-19
AU2018206907A1 (en) 2019-07-11
AU2018206907B2 (en) 2023-11-02
CA3047716A1 (en) 2018-07-19
RU2019123735A3 (es) 2021-03-26

Similar Documents

Publication Publication Date Title
MX2022015500A (es) Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
AR071003A1 (es) Farmaco contra cancer de higado
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
DE602007008524D1 (de) Spiroimidazol-derivate als ppar-modulatoren
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
SA519410204B1 (ar) تركيبة تستهدف s1pr4 من أجل الوقاية من التهاب الكبد الدهني غير الكحولي أو علاجه
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
PH12016502352A1 (en) Pharmaceutical composition
IN2014DN08582A (es)
MA39443A1 (fr) Nouvelle formulation de méloxicam
MX2021000700A (es) Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
CL2019000625A1 (es) Combinación de agonistas de fxr.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
BR112017013845A2 (pt) derivados de glucagon
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine